Even though NPY has been related with lipid and adiposity abnormalities, which have a key role in NAFLD development, the mechanism of the regulatory effects of NPY is still unknown; however, an NPY antagonist could be a novel target in pharmacological options for obesity and NAFLD. Here, NPY is linked to metabolic dysfunction-associated steatotic liver disease.